Podcast: Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic Prostate Cancer
JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, “Digital Pa [...]
The Future of AI in Urology
Artificial intelligence (AI) has become a disruptor in nearly every sector, including health care. In a recent interview with [...]
How ArteraAI is changing prostate cancer treatment through AI-powered diagnostics
Roupen Odabashian, Internal Medicine Physician and Hematology/Oncology Fellow at Karmanos Cancer Institute, shared a post on [...]
Using AI-Powered Diagnostics to Identify Optimal Therapies for Prostate Cancer with Andre Esteva Artera
Andre Esteva is the CEO and Co-Founder of Artera, a company focused on improving prostate cancer diagnostics. The company use [...]
Predicting Cancer Treatment Response
One of the greatest fantasies in medicine is to one day be able to offer any patient a therapy perfectly adapted to their pro [...]
How AI personalizes cancer therapy
From images of patients' digitized pathology, AI gets a view of cells of the tumor for recommended therapy and long- term pro [...]
Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO
In this latest episode of Exploring Artificial Intelligence in Oncology, Fellows Forum member Dr. Waqas Haque sits down with [...]
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer – Phuoc Tran & Tim Showalter
Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in..
AI’s Role in Predicting Cancer Treatment Outcomes
In this episode of the Target Cancer Podcast, Dr. Sanjay Juneja talks with Dr. Tim Showalter, CMO at Artera, about using AI t [...]